Efficacy of postoperative polymyxin B hemoperfusion in secondary peritonitis patients with septic shock

A propensity-matched analysis

Kuo Ching Yuan, Shang Yu Wang, Ming Chin Yu, Yu Pao Hsu, Heng Chih Pan, Yung Chang Chen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Severe sepsis and septic shock is still a challenge. Polymyxin B hemoperfusion (PMX) is a device designed to remove circulating endotoxin by adsorption, which is reported to improve treatment outcomes. This study aimed to further verify the efficacy of PMX on postoperative, peritonitis, septic shock patients. Methods: This study prospectively analyzed 20 of 155 patients who presented with postoperative septic shock and were treated with PMX in a single institute during the period March 2013 to September 2014 (Clinical Trial Protocol number: ChiCTR-ONC-16008160). A control group (53 patients) was recruited from our own 2012 database using the propensity-matching score method. The data collection includes demographic data, postoperative organ dysfunction status, disease severity and treatment result. Results: The 2 groups (treatment vs. control) were similar in demographic data, organ dysfunction status and disease severity. PMX use provides benefits for recovery of hemodynamic status and many other aspects, including better survival, but is not statistically significant. For survival factor analysis, PMX use is also not significant for patient survival in our study. Conclusions: PMX provided some benefits to patients in the treatment for peritonitis septic shock. An improvement in hemodynamic status was mostly observed. Our study also supports the finding that PMX used as an auxiliary treatment provides improved survival but is not statistically significant, possibly due to the small sample size with multiple comorbidities.

Original languageEnglish
Pages (from-to)603-610
Number of pages8
JournalInternational Journal of Artificial Organs
Volume39
Issue number12
DOIs
Publication statusPublished - Dec 1 2016
Externally publishedYes

Fingerprint

Polymyxin B
Hemodynamics
Endotoxins
Adsorption
Factor analysis
Recovery

Keywords

  • Endotoxin
  • Hemoperfusion
  • Peritonitis
  • Sepsis
  • Septic shock

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomaterials
  • Biomedical Engineering

Cite this

Efficacy of postoperative polymyxin B hemoperfusion in secondary peritonitis patients with septic shock : A propensity-matched analysis. / Yuan, Kuo Ching; Wang, Shang Yu; Yu, Ming Chin; Hsu, Yu Pao; Pan, Heng Chih; Chen, Yung Chang.

In: International Journal of Artificial Organs, Vol. 39, No. 12, 01.12.2016, p. 603-610.

Research output: Contribution to journalArticle

Yuan, Kuo Ching ; Wang, Shang Yu ; Yu, Ming Chin ; Hsu, Yu Pao ; Pan, Heng Chih ; Chen, Yung Chang. / Efficacy of postoperative polymyxin B hemoperfusion in secondary peritonitis patients with septic shock : A propensity-matched analysis. In: International Journal of Artificial Organs. 2016 ; Vol. 39, No. 12. pp. 603-610.
@article{137c4a7a34ff41bc90327fa62b1ea408,
title = "Efficacy of postoperative polymyxin B hemoperfusion in secondary peritonitis patients with septic shock: A propensity-matched analysis",
abstract = "Introduction: Severe sepsis and septic shock is still a challenge. Polymyxin B hemoperfusion (PMX) is a device designed to remove circulating endotoxin by adsorption, which is reported to improve treatment outcomes. This study aimed to further verify the efficacy of PMX on postoperative, peritonitis, septic shock patients. Methods: This study prospectively analyzed 20 of 155 patients who presented with postoperative septic shock and were treated with PMX in a single institute during the period March 2013 to September 2014 (Clinical Trial Protocol number: ChiCTR-ONC-16008160). A control group (53 patients) was recruited from our own 2012 database using the propensity-matching score method. The data collection includes demographic data, postoperative organ dysfunction status, disease severity and treatment result. Results: The 2 groups (treatment vs. control) were similar in demographic data, organ dysfunction status and disease severity. PMX use provides benefits for recovery of hemodynamic status and many other aspects, including better survival, but is not statistically significant. For survival factor analysis, PMX use is also not significant for patient survival in our study. Conclusions: PMX provided some benefits to patients in the treatment for peritonitis septic shock. An improvement in hemodynamic status was mostly observed. Our study also supports the finding that PMX used as an auxiliary treatment provides improved survival but is not statistically significant, possibly due to the small sample size with multiple comorbidities.",
keywords = "Endotoxin, Hemoperfusion, Peritonitis, Sepsis, Septic shock",
author = "Yuan, {Kuo Ching} and Wang, {Shang Yu} and Yu, {Ming Chin} and Hsu, {Yu Pao} and Pan, {Heng Chih} and Chen, {Yung Chang}",
year = "2016",
month = "12",
day = "1",
doi = "10.5301/ijao.5000549",
language = "English",
volume = "39",
pages = "603--610",
journal = "International Journal of Artificial Organs",
issn = "0391-3988",
publisher = "Wichtig Publishing",
number = "12",

}

TY - JOUR

T1 - Efficacy of postoperative polymyxin B hemoperfusion in secondary peritonitis patients with septic shock

T2 - A propensity-matched analysis

AU - Yuan, Kuo Ching

AU - Wang, Shang Yu

AU - Yu, Ming Chin

AU - Hsu, Yu Pao

AU - Pan, Heng Chih

AU - Chen, Yung Chang

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Introduction: Severe sepsis and septic shock is still a challenge. Polymyxin B hemoperfusion (PMX) is a device designed to remove circulating endotoxin by adsorption, which is reported to improve treatment outcomes. This study aimed to further verify the efficacy of PMX on postoperative, peritonitis, septic shock patients. Methods: This study prospectively analyzed 20 of 155 patients who presented with postoperative septic shock and were treated with PMX in a single institute during the period March 2013 to September 2014 (Clinical Trial Protocol number: ChiCTR-ONC-16008160). A control group (53 patients) was recruited from our own 2012 database using the propensity-matching score method. The data collection includes demographic data, postoperative organ dysfunction status, disease severity and treatment result. Results: The 2 groups (treatment vs. control) were similar in demographic data, organ dysfunction status and disease severity. PMX use provides benefits for recovery of hemodynamic status and many other aspects, including better survival, but is not statistically significant. For survival factor analysis, PMX use is also not significant for patient survival in our study. Conclusions: PMX provided some benefits to patients in the treatment for peritonitis septic shock. An improvement in hemodynamic status was mostly observed. Our study also supports the finding that PMX used as an auxiliary treatment provides improved survival but is not statistically significant, possibly due to the small sample size with multiple comorbidities.

AB - Introduction: Severe sepsis and septic shock is still a challenge. Polymyxin B hemoperfusion (PMX) is a device designed to remove circulating endotoxin by adsorption, which is reported to improve treatment outcomes. This study aimed to further verify the efficacy of PMX on postoperative, peritonitis, septic shock patients. Methods: This study prospectively analyzed 20 of 155 patients who presented with postoperative septic shock and were treated with PMX in a single institute during the period March 2013 to September 2014 (Clinical Trial Protocol number: ChiCTR-ONC-16008160). A control group (53 patients) was recruited from our own 2012 database using the propensity-matching score method. The data collection includes demographic data, postoperative organ dysfunction status, disease severity and treatment result. Results: The 2 groups (treatment vs. control) were similar in demographic data, organ dysfunction status and disease severity. PMX use provides benefits for recovery of hemodynamic status and many other aspects, including better survival, but is not statistically significant. For survival factor analysis, PMX use is also not significant for patient survival in our study. Conclusions: PMX provided some benefits to patients in the treatment for peritonitis septic shock. An improvement in hemodynamic status was mostly observed. Our study also supports the finding that PMX used as an auxiliary treatment provides improved survival but is not statistically significant, possibly due to the small sample size with multiple comorbidities.

KW - Endotoxin

KW - Hemoperfusion

KW - Peritonitis

KW - Sepsis

KW - Septic shock

UR - http://www.scopus.com/inward/record.url?scp=85012241690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012241690&partnerID=8YFLogxK

U2 - 10.5301/ijao.5000549

DO - 10.5301/ijao.5000549

M3 - Article

VL - 39

SP - 603

EP - 610

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

SN - 0391-3988

IS - 12

ER -